Cleantech and life sciences company BioLargo Inc, through its subsidiary, Clyra Medical Technologies, has introduced ViaCLYR™, a wound irrigation solution suitable for acute and chronic wounds and burns with an impressive 99.9999% kill rate while at the same time remaining gentle and non-toxic to the body.
The company’s first commercial stocking order from Advanced Solution LLC order marks the beginning of commercial distribution and signifies Clyra's shift from development-stage operations to generating early revenue.
This development was followed by a February 18th press release in which BioLargo reported recent clinical results as presented by a leading clinical expert in the wound care field.
Dr. Marcus Gitterle, who serves as Regional Medical Director for Wound Care and Hyperbaric Oxygen Therapy for the Christus Santa Rosa Hospital System in San Antonio, Texas, and Co-founder and Chief Medical Officer of Wound Centrix LLC, presented clinical results from a multi-site evaluation involving approximately 36 cases across four wound clinics over a four-month period. The presentation at a leading clinical conference highlighted outcomes across challenging wound care settings, including diabetic foot ulcers, venous leg ulcers, pressure injuries, and complex surgical wounds.
The clinical experience demonstrated what Dr. Gitterle described as "remarkable" and "unusual" results, with ViaCLYR™ showing excellent safety, strong antimicrobial performance, and notably enhanced healing characteristics. Importantly, clinicians reported no adverse reactions during the evaluation period, reinforcing ViaCLYR™'s favorable safety and tolerability profile.
According to estimates from the CDC and peer-reviewed studies, hundreds of thousands of patients in the United States develop infections during hospital stays each year, contributing to billions of dollars in additional healthcare costs and extended hospitalizations. Infection control in wound care — particularly for acute, chronic, and burn-related injuries — represents a critical component of this broader challenge. A recent scholarly study published by the Cambridge University Press reported direct costs associated with hospital-acquired infections to range from a low of $7.2 billion to as high as $45 billion per year.
"This commercial order reflects years of disciplined development, regulatory execution, and commercial preparation," said Steve Harrison, Clyra's chief executive officer. "With ViaCLYR™ now entering the distribution channel, we are beginning the transition from innovation to execution, laying the groundwork for scalable revenue growth as adoption expands."
"The clinical experience shared underscores what we designed ViaCLYR™ to achieve effective antimicrobial support that works with the body, not against it," said Steve Harrison, "Having an independent clinician of Dr. Gitterle's stature describe real-world performance that exceeds expectations, presented to a highly respected audience of wound care specialists, represents important validation as we continue our commercial rollout."
These milestones are the first in a series of planned commercial and revenue-related announcements as Clyra progresses its market rollout, according to Harrison.
ViaCLYR™ is a highly effective, tissue-safe, long-acting wound irrigation solution suitable for acute and chronic wounds and burns. The unique, clear, odorless, non-irritating solution is 510(k) cleared by the FDA and indicated for acute and chronic wounds. It boasts extremely high antimicrobial activity as a preservative in solution, with over 99.9999% kill rate (up to 7 log reduction) and sustained efficacy for up to 72 hours, according to Dennis P. Calvert, Chairman of Clyra Medical Technologies and CEO of BioLargo.
"These milestones," he says, "represents tangible steps forward in BioLargo's strategy of developing differentiated technologies and advancing them into commercial markets through strong partnerships. Clyra is well positioned to build momentum as product availability expands and market awareness grows. We believe it may well become a new standard of care."
BioLargo and its co-investors have invested approximately $25M into its subsidiary Clyra Medical to bring to market its wound-care solutions. “The industry has never seen a solution like ours that combines effectiveness, sustained efficacy and gentleness the way these products perform. While the journey has been long and challenging, we believe the impact these products will make for human health will be dramatic and worth every step and every dollar.” Calvert says.
Clyra's commercial readiness reflects the completion of key foundational elements, including FDA 510(k) clearance, implementation of ISO 13485-certified quality systems, validated manufacturing processes, and clinical evaluations supporting real-world use, Calvert notes.
“As distribution begins,’ he says, “Clyra plans to advance additional commercialization initiatives and expand its product portfolio over time.”
Clyra is a partially owned subsidiary of BioLargo that focuses on infection control and advanced wound care. Founded in 2012, the company develops and commercializes wound care solutions based on its proprietary Copper-Iodine Complex Technology. Clyra's product portfolio features FDA-cleared medical devices that leverage this patented technology to deliver superior wound care outcomes.
Progress on Multiple Platforms
Calvert recently shared an open letter with shareholders outlining BioLargo’s positioning within a number of high growth industries in which is intends to make comparable transformation as to what is is now on track to do with Clyra.
While Clyra’s commercialization marks a pivotal milestone in healthcare, BioLargo’s broader portfolio targets similarly large and structurally growing markets. The company’s Aqueous Electrostatic Concentrator (AEC) platform is focused on addressing PFAS contamination and advanced water treatment challenges, positioning BioLargo within the rapidly expanding environmental remediation sector driven by tightening federal and state regulations.
In energy storage, BioLargo’s Cellinity subsidiary is pursuing grid-scale battery solutions designed to support renewable integration, microgrid deployment, and increasing power demand driven by electrification and data infrastructure expansion. Management views long-duration and rapid-response storage as critical components of next-generation energy systems.
Across platforms, the strategy remains consistent: develop differentiated technologies, validate them rigorously, secure regulatory and technical credibility, and then transition into commercialization through strategic partnerships. Clyra’s progression from development to early revenue generation is viewed as a blueprint for how the company intends to replicate success across its other high-impact platforms.
Calvert’s service on the U.S. Department of Commerce’s Environmental Technologies Trade Advisory Committee (ETTAC) further strengthens this positioning. In that role, he works directly with policymakers to help shape trade and competitiveness strategies for U.S. environmental technology companies. This perspective provides BioLargo with insight into global infrastructure investment trends, regulatory momentum, and export opportunities — aligning the company’s platforms with national and international strategic priorities.
Management believes that the convergence of environmental regulation, infrastructure modernization, and energy transition initiatives creates a multi-year tailwind across BioLargo’s portfolio, with Clyra representing the first of several platforms moving from validation to commercial execution.
Calvert stated, “Observers often comment on our ‘multiple shots on goal’ as a key attribute, but rest assured, we fully expect every one of our key technologies to ‘hit the target’. Years of discipline, careful investment, highly qualified team members and a mission focused on transformative impact will be our hallmark."
Copyright © 2026 California Business Journal. All Rights Reserved.
For California Business Journal Disclaimers, go to /terms-conditions/.
